Edison Investment Research - Smith Nephew (SN) QuickView: New growth strategy has legs

Report

Edison Investment Research

QuickView: New growth strategy has legs

Smith & Nephew delivered a fair Q4 and inspired confidence in a broadly based improvement of underlying revenue and earnings growth in 2015e and beyond. We believe its five-pillar strategy (innovation, simplification, acquisitions and growth in established and emerging markets) is gaining ground in the increasingly competitive market focused on value for money.

09/02/2015 2 EN

Underlying

Smith & Nephew

See profile

United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

QuickView: Stronger H2 needed to deliver 2016 targets

Smith & Nephew (S&N) reported slower revenue growth in H116 than management expectations, due principally to the trading problems experienced by the sector in the emerging markets, particularly China and the Middle East. The company indicates that this is improving, as China starts to return to growth (as seen in the Sports Medicine division in Q2), but we expect the weakness to continue through H2. Its 6% premium on 2016e P/E to the average of its global orthopaedic peers is supported by its leading position in innovative areas such as robotics, although to maintain this it needs to continue ...

August 2, 2016 August 2, 2016 2 EN

Edison Investment Research

Update: Growth on an accelerating path

Smith & Nephewâ€™s growth acceleration and margin expansion in Q2 should continue in H215, more reflecting internal changes than improvements in market fundamentals. Its c 13% premium on 2015 P/E to its global ortho peers is supported by its brisker growth and strategic value.

September 9, 2015 September 9, 2015 2 EN

Edison Investment Research

QuickView: Well placed to deliver on 2015 targets

Smith & Nephewâ€™s Q115 was bolstered by a recovery in Advanced Wound Care, the ArthroCare integration and its emerging markets exposure. We believe the company is well on track to raise its sales growth and trading profit margin in FY15e. Its 16% FY15 P/E premium to its global orthopaedic peers is supported by its improving growth profile and its strategic value.

May 7, 2015 May 7, 2015 2 EN

Record - AUME momentum and a sharper focus

Record’s Q424 trading update demonstrated continued growth in assets under management equivalent (AUME), which will support management fee growth into FY25. In FY24, AUME grew 17% to US$102.2bn, setting a new milestone in business scale. Net inflows for FY24 were US$6.8bn (FY23: US$9.1bn) or 8% of opening AUME. Performance fees of US$5.8m matched the record FY23 figure, and we expect this to offset the negative product mix in FY24. We have reduced our FY24e EPS by 1%, which is affected by £2.4bn in IT restructuring and impairment charges announced in March 2024. New CEO Dr Jan Witte is putting...

15h / 28m 15h / 28m 1 EN

Sean Conroy

Sean Conroy

Actinogen Medical - Funding in place through key catalysts

Actinogen announced a capital increase of up to A$8.9m on 3 May, consisting of a A$5.0m (gross) placement along with a shareholder rights offering (‘entitlement offer’) designed to raise up to A$3.9m (gross) from existing shareholders. The closing date of the rights offer is 29 May and, given that Actinogen shares are currently trading at c A$0.028, we assume full exercise of the rights offering in Q424 (Q2 CY24). The company expects that the proceeds (assuming full exercise of the rights offering) will extend its operating runway beyond the interim results release of the first 100 patients of...

May 15, 2024 May 15, 2024 1 EN

Pedro Fonseca

Pedro Fonseca

Henderson Opportunities Trust - A differentiated exposure to smaller companies

With a focus on long-term growth, Henderson Opportunities Trust (HOT) seeks investment opportunities across the breadth of the UK market. This includes a strong bias towards smaller and earlier-stage companies with significant potential to become tomorrow’s leading British businesses. There are tentative signs that the significant three-year underperformance of these smaller companies, and of HOT, may be coming to an end. If so, the trust is well placed to benefit and its differentiated, truly all-market approach is one that many investors would struggle to replicate. Moreover, HOT’s size and ...

May 15, 2024 May 15, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: New growth strategy has legs

QuickView: Stronger H2 needed to deliver 2016 targets

Update: Growth on an accelerating path

QuickView: Well placed to deliver on 2015 targets

Record - AUME momentum and a sharper focus

Actinogen Medical - Funding in place through key catalysts

Henderson Opportunities Trust - A differentiated exposure to smaller companies

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe